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Abstract
Background
The WHO recommends artemisinin-based combination therapies (ACTs) for the treatment
of uncomplicated falciparum malaria. Hence, monitoring the efficacy of antimalarial drugs is
a key component of malaria control and elimination. The published randomized trials that
assessed comparisons of ACTs for treating uncomplicated falciparum malaria reported con-
flicting results in treatment efficacy. A network meta-analysis is an extension of pairwise
meta-analysis that can synthesize evidence simultaneously from both direct and indirect
treatment comparisons. The objective was to synthesize evidence on the comparative effi-
cacy of antimalarial drugs for treatment of uncomplicated falciparum malaria in Asian
region.
Methods
Relevant randomized trials that assessed efficacy of antimalarial drugs for patients having
uncomplicated falciparum malaria in Asian region were searched in health-related data-
bases. We evaluated the methodological quality of the included studies with the Cochrane
risk of bias tool. Main outcome was treatment success at day 28 as determined by the
absence of parasiteamia. We performed network meta-analysis of the interventions in the
trials, and assessed the overall quality of evidence using the GRADE approach.
Results
Seventeen randomized trials (n = 5043) were included in this network meta-analysis study.
A network geometry was formed with 14 antimalarial treatment options such as artemether-
lumefantrine (AL), artemisinin-piperaquine, artesunate-amodiaquine, artesunate-meflo-
quine (ASMQ), artesunate-chloroquine, artesunate-mefloquine home treatment, artesu-
nate-mefloquine 2-day course, artesunate plus sulfadoxine-pyrimethamine, chloroquine,
dihydroartemisinin-piperaquine (DHP), dihydroartemisinin-piperaquine home treatment,
dihydroartemisinin-piperaquine 4-day course, dihydroartemisinin-piperaquine and added
PLOS ONE | https://doi.org/10.1371/journal.pone.0225882 December 19, 2019 1 / 16
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Naing C, Whittaker MA, Htet NH, Aye SN,
Mak JW (2019) Efficacy of antimalarial drugs for
treatment of uncomplicated falciparum malaria in
Asian region: A network meta-analysis. PLoS ONE
14(12): e0225882. https://doi.org/10.1371/journal.
pone.0225882
Editor: Gordon Langsley, Institut national de la
sante´ et de la recherche me´dicale - Institut Cochin,
FRANCE
Received: September 24, 2019
Accepted: November 14, 2019
Published: December 19, 2019
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pone.0225882
Copyright: © 2019 Naing et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
artesunate, sulfadoxine-pyrimethamine. A maximum number of trials included was DHP
compared to ASMQ (n = 5). In general, DHP had better efficacy than AL at day 28 (DHP vs
AL: OR 2.5, 95%CI:1.08–5.8). There is low certainty evidence due to limited number of stud-
ies and small trials.
Discussion/ Conclusions
The findings suggest the superiority of DHP (3–day course) to AL and other comparator
ACTs are with the overall low/very low quality of evidence judgements. Moreover, one drug
regimen is better than another is only if current drug-resistance patterns are at play. For
example, the AL might be better than DHP in areas where both artemisinin and piperaquine
resistance patterns are prevalent. For substantiation, well-designed larger trials from
endemic countries are needed. In the light of benefit versus harm concept, future analysis
with safety information is recommended.
Introduction
Malaria caused by Plasmodium falciparum is responsible for>90% of malaria cases and almost
all of the malaria deaths worldwide. According to the WHO report, there was no significant
progress in reducing global malaria during the period 2015–2017 [1]. The Global technical
strategy (GTS) 2020 milestones include the elimination of malaria in at least 10 countries that
were malaria endemic in 2015 [2]. In fact, malaria is a preventable and curable disease. The
WHO recommends artemisinin-based combination therapies (ACTs) for the treatment of
uncomplicated malaria caused by P. falciparum. The primary advantage of the combination
therapy is that the artemisinin quickly and drastically reduces the majority of malaria parasites,
and the partner drug clears remaining small number of parasites [3,4]. Thus far, ACTs is the
newest class of antimalarials that are used worldwide including in the Greater Mekong Sub-
region (GMS). There are reports on evidence of artemisinin resistant hotspots in Cambodia,
Thailand and on the Thai-Myanmar border [1,2]. The emergence of falciparum resistance to
artemisinins would not only limit treatment options in the affected areas, but could also com-
promise the management of uncomplicated malaria cases in other areas where ACT is widely
recommended [5]. Containment of parasites developing resistance to anti-malarial drugs is
one of the major goals to progress from malaria control towards elimination [4,5]. Hence,
monitoring the efficacy of antimalarial drugs is a key component of malaria control and subse-
quent elimination.
Five ACTs recommended by WHO for treatment of uncomplicated P. falciparum malaria
are: artemether—lumefantrine (AL), artesunate- amodiaquine (ASAQ), artesunate- meflo-
quine (ASMQ), artesunate plus sulfadoxine-pyrimethamine (ASSP) and dihydroartemisinin-
piperaquine (DHP) [3,5]. Protecting the efficacy of ACTs as the current first- and second-line
treatment for P.falciparum malaria is one of a top global public health priority [1,3]. However,
the question is which antimalarial drugs offers the greatest benefits (efficacy) for treatment of
uncomplicated P. falciparum malaria at day 28? There are published Cochrane systematic
reviews [6,7] and non-Cochrane systematic reviews/meta-analyses [8,9], assessing head-to-
head comparisons of ACTs for treating uncomplicated P.falciparum malaria. These reviews
reported conflicting results. For example, a review by Zani and associates reported that in
Africa, there was better efficacy in DHP than AL at day 28. However, such relationship was not
A network meta-analysis of treatment efficacy for uncomplicated falciparum malaria
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shown in Asia [7]. This reflects that efficacy of antimalarial is related to whether the area is
with artemisinin-sensitive parasite populations or not [7,9]. Hence, we performed a network
meta-analysis (NMA) that can synthesize evidence simultaneously from both direct and indi-
rect treatment comparisons [10]. For instance, even when no head-to-head trial is available,
studies evaluating A versus B and B versus C can be used to compare A and C indirectly
through the NMA approach. Indirect comparisons must be connected by at least one common
comparator (i.e. treatment B in this example). An assumption required for the NMA is ‘transi-
tivity’ that trials should be comparable in all characteristics [11]. On the whole, the objective of
present study was to synthesize evidence on the comparative efficacy of currently used antima-
larial drugs for treatment of uncomplicated falciparum malaria in Asian region.
Materials and methods
The current study adhered to the preferred reporting items for network meta-analyses (PRIS-
MA-NMA) [12] (S1 Table).
Search strategy
We searched relevant studies in the health-related electronic database including MEDLINE,
Medline-in-Process, OLD Medline, EMBASE, and the Cochrane library using the texts includ-
ing “malaria” “Artemisinin-based combination therapy”, “randomized trial” “humans” with
Boolean operators. The search was done according to guidance provided in the Cochrane
Handbook for Systematic Reviews of Interventions [13] and in consultation with an informa-
tion specialist. The search strategies for the MeSH terms are listed in S2 Table. Additionally,
we searched in, ClinicalTrials.gov, EU Clinical Trials Register and WHO International Clinical
Trials Registry Platform for ongoing trials. Search was limited to studies published in English
language until June 2019.
Selection of study
Eligible studies were identified through the PICOS format [13].
Study Population (P): Participants having uncomplicated falciparum malaria residing in
Asian region, regardless of gender and age were included.
Uncomplicated malaria caused by the P. falciparum parasite in this study is defined as
patients having symptoms that are non-specific in the presence of P. falciparum, but in the
absence of clinical or laboratory findings of severe organ dysfunction.
An operational definition of the Asian region for this particular study covers countries in
three regions of Southeast Asia, South Asia and East Asia.
Interventions (I): Anti-malarial drugs for the treatment of uncomplicated falciparum
malaria were considered. Different dosages of an antimalarial regimen were considered as
individual treatments.
Comparisons (C): An alternative antimalarial drug or placebo were included.
Study Outcomes (O): Main outcome was cure rate at day 28 (defined as the proportion of
patients with clearance of asexual P. falciparum parasitaemia within seven days of initiation of
trial drug, without subsequent recrudescence within 28 days after initiation of study). Recru-
descence was defined as the existence of positive blood smears after initial clearance of para-
sites from the peripheral blood [14].
Study design (S): Randomised clinical trials (RCT), conducted in Asian region.
Studies were excluded, if they did not meet the inclusion criteria. Studies on pregnant
women and travellers were not considered.
A network meta-analysis of treatment efficacy for uncomplicated falciparum malaria
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Data extraction and management
One investigator (SNA) screened title and abstracts on the basis of RCTs that assessed human
falciparum malaria. The same investigator extracted information from the RCTs included.
Information collected were study characteristics, intervention and comparators and outcomes.
Information collected were cross-checked by another investigator (CN). Any discrepancies
were settled by discussion.
Methodological quality assessment
The methodological quality of the RCTs was evaluated using the Cochrane risk of bias tool
[13]. Three domains (adequate sequence generation, allocation concealment and blinding of
participants and outcome assessors) were assessed for the risk of bias assessment for each trial.
The ratings were noted (i.e. high risk, unclear risk, low risk) for the risk of bias category in sub-
sequent Grading of Recommendations Assessment, Development, and Evaluation (GRADE)
assessment. [15].
Data synthesis
Main outcome in this review was treatment success (cure rate) by anti-malarial treatment at
day 28. We preferred the intention-to-treat (ITT) analysis over another analysis, whenever it
was available. We performed pair-wise meta-analyses of all available within-study compari-
sons, followed by subsequent network meta-analyses.
Pairwise comparison: When the studies reported in similar ways, we did head-to-head
comparisons as a direct pairwise meta-analyses. An odds ratio (OR) and its 95%confidence
interval (CI) were computed for the dichotomous variables. Between-study heterogeneity was
assessed with the I2 statistic. We pooled ORs with a DerSimonian-Laird random-effects model
in the presence of substantial heterogeneity (I2>50%). Publication bias was investigated with
the contoured-enhanced funnel plot [13].
Network meta-analyses: We performed NMA within a frequentist framework using ran-
dom-effects models [16–18]. We established network mapping. An assumption of NMA is
‘transitivity’ that the trials comparing different sets of interventions should be similar enough
in their characteristics [11]. We also investigated another assumption of NMA such as network
‘inconsistency’ (i.e. disagreement between the different sources of evidence) with the use of the
global Wald test for inconsistency [19,20]. We also checked, if there were concerns with
‘intransivity’ [21]. For a ranking of the effectiveness, we reported ‘Surface Under the Cumula-
tive Ranking Curve’ (SUCRA) [11, 18]. SUCRA = 1 or 0 was indicated the rank of an interven-
tion drug as first or last, respectively. Statistical significance was set at p value�0.05.
Assessing the quality of evidence
We assessed the quality of evidence derived from the pairwise and NMA, following the GRADE
approach, as described elsewhere [15,17,21,22]. For direct comparison, we rated evidence on the
five categories; study limitations (risk of bias), precision, consistency of results, directness of evi-
dence and publication bias, using the standard GRADE approach. We then evaluated the overall
confidence in estimates of effect for treatment efficacy for each direct comparison as ‘high’, ‘mod-
erate’, ‘low’ or ‘very low’ quality of evidence. For indirect comparison, we rated evidence from the
most dominant first-order loop by first taking the lowest certainty of direct comparisons. We did
not rate on intransitivity [21] in the absence of important imbalance in the distribution of effect
modifiers (e.g. age, gender) across included trials. For NMA mixed estimates, we started with the
higher quality of the two certainty ratings and rated down certainty for incoherence (degree of
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inconsistency between direct and indirect effect estimates) in the final quality rating [21,22]. Data
analysis was employed with STATA 15.0 (StataCorp, TX).
Results
Trials included
Fig 1 illustrates the study selection process. The initial search produced 13640 hits. After
removal of duplicates and screening of titles and abstracts, 34 full-text papers were evaluated
and 17 studies, incorporating 5043 total number of patients were finally selected for this review
[14, 23–38]. The highest number of trials include DHP compared to ASMQ (n = 5), followed
by artemisinin-piperaquine (AMPQ) to DHP (n = 3) and AL to ASMQ (n = 2). A summary of
the 17 excluded studies is provided in S3 Table.
Table 1 provides the key characteristics of the studies identified. The number of participants
varied from 47 [14] to 769 [36]. The majority of participants in the studies included were
males (range from 51% to 96%) with mean age between 5.9 to 29 years. The distribution of
studies is presented in S4 Table. Three studies were three-arm RCTs [23,24,30] and one study
was a four-arm RCT [29] and the remaining 13 studies were two-arm RCT. Studies were con-
ducted in 8 countries such as Cambodia, India, Indonesia, Laos, Myanmar, Nepal, Thailand
and Vietnam. One multi-country study was conducted in India, Laos and Thailand [36].
The number of studies with unclear risk of bias in sequence generation (53%) and that with
high risk of bias in the blinding status was 58.8%. Overall risk of bias assessment revealed that
most studies had an unclear/high risk of bias due to insufficient information on allocation con-
cealment and the blinding status of the RCTs (S5 Table).
Fourteen-node analysis
Fig 2 shows a network plot of treatment success with 14 antimalarial treatment options. These
options of antimalarial regimens included AL, AMPQ, ASAQ, artesunate plus chloroquine
(ASCQ), ASMQ, artesunate-mefloquine home treatment/not supervised (ASMQh), artesunate-
mefloquine 2-day course (ASMQ2), ASSP, chloroquine (CQ), DHP, dihydroartemisinin-piper-
aquine home treatment/not supervised (DHPh), dihydroartemisinin-piperaquine 4-day course
(DHP4), dihydroartemisinin-piperaquine and added artesunate (DHPAS), sulfadoxine-pyri-
methamine (SP). As seen in the present network map, none of the studies compared ASSP and
CQ directly, but each had been compared with a common comparator AL. We may assume an
indirect comparison of ASSP and CQ on the direct comparison of ASSP and AL and the direct
comparison of CQ and AL. Fig 3 presents forest plot with effects for each study, estimates from
direct pairwise meta-analysis and mixed estimate from the network meta-analysis.
Pairwise-analysis of the relative efficacy of antimalarial drugs for treating uncomplicated P.
falciparum malaria was reported that there were comparable cured rates between the treatment
regimens, spanning both benefit and harm, except one comparison (i.e. AL versus CQ) (S1
Fig). For instance, DHP compared to AL in a single trial and there was a superiority of DHP in
cure rate at day 28 (OR 2.5, 95%CI: 1.08 to 5.8) (Table 2). The results of the network meta-
analysis are presented in Fig 4. In general, DHP was better than many comparators in terms of
efficacy at day 28. For instance, DHP was superior to ASCQ (OR: 11.21,95% CI 3.4–36.89). Of
note is that there was small number of studies in many comparisons and 95%CIs were (very)
wide. For instance, DHP versus AL was done in a single study.
The global Wald test showed the presence of consistency in the network [Chi2 (4) = 3.02,
p = 0.8089] (Fig 3). Tests of local incoherence did not show any inconsistent loops for efficacy
at day 28 (S2 Fig). The comparison adjusted funnel plots of the network meta-analysis [39] for
efficacy at day 28 was not suggestive for publication bias (S3 Fig).
A network meta-analysis of treatment efficacy for uncomplicated falciparum malaria
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Treatment relative ranking
Treatment-relative ranking in this network meta-analysis is presented in (S6 Table). DHP had
the highest probability of being the best choice for treating patients with uncomplicated P. fal-
ciparum (S4 Fig). The SUCRA and ranking results are subjected to the small number of partic-
ipants in some studies and wide estimates spanning from benefit to harm. As the evidence on
which the SUCRA rankings are of very low quality, they are untrustworthy [40]. Predictivity
intervals of mixed estimates are presented in Fig 5. Although their confidence intervals suggest
an association, the respective predictive interval crosses the line of no effect and suggests that
future studies might favour either treatment. We therefore made overall evidence through the
GRADE approach rather than the SUCRA rankings (Table 2).
Overall, we observed a low certainty evidence whether any antimalarial regimens included
in this study were better in clearance of parasitemia at day 28 since the certainty of the evi-
dence was assessed as low.
Fig 1. Study selection process.
https://doi.org/10.1371/journal.pone.0225882.g001
A network meta-analysis of treatment efficacy for uncomplicated falciparum malaria
PLOS ONE | https://doi.org/10.1371/journal.pone.0225882 December 19, 2019 6 / 16
Table 1. Characteristics of the studies included in the network meta-analysis.
Author,
Year of
publication
[ref.no]
Study
period
Country Setting Study
arms
Interventions Participants Male Age,
mean in year
(±SD) or
median and
range
PCR Under
supervision
Funding
1 Rachmawati,
2010 [14]
1/2009
- 7/
2009
Indonesia. H
(in-pt)
2 AL,
ASSP
47 59.5% 5.9 ±3.46 No Yes Not reported
2 Ashley,
2004 [23]
7/
2002–
4/2003
Thailand H
(in-pt)
3 ASMQ, DHP,
DHPAS
731 78.1% Adults
(25.3± 8.2)
No Yes Holleykin
Pharmaceutical
3 Ashley,
2005
[24]
4/
2003–
4/ 2004
Thailand OPD 3 ASMQ, DHP,
DHP4
499 60.5% Any age
(21,
3–57)
Yes Yes MMV;
Wellcome
-Mahidol;
Wellcome Great
Britain.
4 Kshirsaga,
2000
[25]
6/
1996–
1/1997
India H
(in-pt)
2 AL, CQ 179 96% 29
(17–66)
Yes Yes
5 Lefevre,
2001
[26]
9/
1998-
1/1999
Thailand H 2 AL,
ASMQ
219 70% 50
(12–71)
Yes Yes Novartis
Pharma AG.
6 Huong,
2003
[27]
NA Vietnam H
(in-pt)
2 ASSP, ASCQ 123 51% Any age,
10.3 ± 11.3
(4–65)
Yes Yes male% & age in
the ASSP gr
7 Silachamroon,
2005
[28]
NA Thailand H
(in-pt)
2 ASMQ,
ASMQ2
120 70.8% Adults
(25.6± 10.1)
No Yes WHO/RBM/
Mahidol
University
8 Smithuis,
2006
[29]
11/
2003 -
4/2004
Myanmar OPD 4 ASMQ,
ASMQh, DHP,
DHPh
652 52% 3 age-gr;
58.2%(5–14
yr)
Yes Yes (Gr1
No (Gr 2)
MSF (Holland);
9 Song,
2011
[30]
7/2005
-
10/
2005
Cambodia H
(in-pt)
3 AL,
AMPQ,DHP
220 73% 3 age-gr; 80%
(>15 yr).
Yes Yes Science &
Technology
Planning Project,
MOST/China
10 Thanh,
2009
[31]
9/2006
-
12/
2007.
Vietnam Health
station
2 DHP,
AMPQ
116 63.8% Any age;
(20.6± 12.4)
Yes Yes People’s Army
Department of
Military Medicine
11 Thanh,
2012
[32]
5/
2008–
12/
2009,
Vietnam Commune
centre
2 ASAQ, DHP 128 70.1% Any age;
(18.9± 12.7)
Vietnam
People’s Army
Department of
Military Medicine
12 Thapa,
2007
[33]
8/
2005–
10/
2005.
Nepal H
(in-pt)
2 AL, SP 99 53%
(AL);
73%
(SP)
>5 yr;
(26.5 ± 13.8)
Yes Yes Not reported
13 Tjitra,
2001
[34]
2007–
2008
Indonesia 4 Hs 2 ASSP, SP 105 60% 83.8%
(under 12 yr)
Yes Yes Nicholson-Hill
Malaria Research
Fund & Tudor
Foundation.
14 Trung,
2009
[35]
NA Vietnam, treatment
center (in-
pt)
2 DHP, AMPQ 103 61.2% 25.8±13.9 Yes Yes Science and
Technology
Research Projects
of
Guangdong
Province
(Continued)
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Discussion
Summary of main results
The present network meta-analysis, including 14 different antimalarial interventions from 17
RCTs studies, provided both direct and indirect evidences regarding the relative efficacy at the
end of 28-day follow-up time. This approach provided both direct and indirect information
through the use of a common comparator to obtain estimates of the relative effects on multi-
ple-intervention comparisons. To our knowledge, this is the first comprehensive synthesis of
data from available antimalarial interventions for treatment of uncomplicated falciparum
malaria in Asia.
If parasite populations are not completely eradicated from the patient, low-level replication
continues until it reaches the microscopic or clinical detection threshold to cause a treatment
failure (i.e. recrudescent infection). The parasitological cure rates at day 28 is potentially a
more sensitive marker for in vivo efficacy of an antimalarial drug compared to the cure rates at
day 14. This is particularly for drugs with long half-lives in plasma. But, it is also applicable to a
certain me extent to drugs with short plasma half-lives. Therefore, the end point of PCR-cor-
rected cure rate at day 28 in the current analysis is an acceptable outcome measure to increase
the sensitivity of the test as well as to generate appropriate data for a comparison of the differ-
ent treatment regimens (artesunate alone versus the combination of artesunate and AMQ)
[41]. Overall, the results of this NMA provided low quality evidence that no regimen could
provide better rates of treatment success, except DHP.
Artemisinin resistance to parasites have shown reduced susceptibility and is clearly associ-
ated with increasing rate of failure of ACT in Cambodia [42] and Thailand [43]. K13-propeller
mutation was identified as a key determinant of artemisinin resistance in Southeast Asia [44].
Many administrative regions in Myanmar had combined K13-propeller mutation prevalence
of more than 20% [45], including regions on the Myanmar India border areas.
Table 1. (Continued)
Author,
Year of
publication
[ref.no]
Study
period
Country Setting Study
arms
Interventions Participants Male Age,
mean in year
(±SD) or
median and
range
PCR Under
supervision
Funding
15 Valecha,
2010
[36]
NA Multi
country
(India,
Laos,
Thailand)
OPD 2 DHP, ASMQ 1150 78.4% mainly adults,
(25.46±
13.3)
Yes Yes MMV,
Sigma Tau. &
Oxford University
16 van Vgt,2000
[37]
11/
1997-
3/1998
Thailand H & health
camp
2 AL,
ASMQ
200 73.5% Adults &
children
(23, 13–63)
Wellcome Trust
of Great Britain
17 Wilairatana,2002
[38]
?? Thailand H
(in-pt)
2 DHP,
ASMQ
352 66.8% 24.8
(±13.3)
No Yes Tonghe
Phramaceutical
Co. Ltd
AL: Artemether-lumefantrine; AMPQ; artemisinin-piperaquine; ASMQ: artesunate-mefloquine; ASMQh: artesunate-mefloquine home treatment/not supervised;
ASMQ2: artesunate-mefloquine 2-day course; ASAQ; artesunate-amodiaquine; ASCQ: artesunate-chloroquine; ASSP: artesunate plus sulfadoxine-pyrimethamine; CQ:
chloroquine; DHP: dihydroartemisinin-piperaquine; DHP4: dihydroartemisinin-piperaquine 4-day course; DHPh; dihydroartemisinin-piperaquine home treatment/
not supervised; DHPAS dihydroartemisinin-piperaquine & artesunate added; SP: sulfadoxine-pyrimethamine; gr: group(s); H; hospital; In-pt: Inpatients; MMV:
Medicines for Malaria Venture; MOST/China: Ministry of Science and Technology of the People’s Republic of China; MSF: Medecins Sans Frontieres; OPD: outpatient
department/centre; WHO/RBM: World Health Organization/Roll Back Malaria’ yr: year.
https://doi.org/10.1371/journal.pone.0225882.t001
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ACT is recommended to be given for three days along with slowly eliminated partner drug.
In a three-day regimen, the artemisinin component stays in body for two asexual parasite life-
cycles, except for P. malariae. In each asexual cycle, artemisinin and its derivatives reduce par-
asite counts by a factor of almost 10,000 [47,48]. The current NMA showed that there is a very
low-certainty evidence that DHP (3-day course) was superior to other ACTs (ASAP, AL,
ASAQ, ASMQ). A published NMA of antimalarial treatments for uncomplicated falciparum
malaria in African children that included 12 RCTs showed superiority of DHP among cur-
rently WHO recommended ACTs [46], but it did not report an overall quality of evidence.
The utility of DHP is an important information in drug compliances as AL has to be adminis-
tered twice daily for three days and it also need to take fatty food to be effective. Moreover, the
treatment cost of AL is also more expensive (>10 US$ per treatment course) [46].
Study limitations
Studies in other languages may have been missed, if abstracts in English language are not
available. Future study, addressing the cost-effectiveness of particular antimalarial drug
Fig 2. Network plot of the antimalarials for treating P. falciparum malaria.
https://doi.org/10.1371/journal.pone.0225882.g002
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Fig 3. All direct and mixed comparisons.
https://doi.org/10.1371/journal.pone.0225882.g003
Table 2. GRADE quality of evidence for the comparative efficacy of antimalarial.
Treatment
comparison
Direct estimate; OR (95% CI) Quality of
evidence
Indirect estimate;
OR (95% CI)
Quality of
evidence
Network estimate; OR
(95% CI)
Quality of
evidence
DHP vs AL 1.29
(0.74 to 2.23)
1 fewer per 1,000
(from 2 fewer to 1 fewer)
⊕◯◯◯d,e
VERY LOW
2.5
(1.08 to 5.8)
3 fewer per 1,000
(from 6 fewer to 1 fewer)
⊕⊕◯◯a
LOW
2.5
(1.08 to 5.8)
3 fewer per 1,000
(from 6 fewer to 1 fewer)
⊕⊕◯◯a
LOW
DHP vs ASCQ NA NA 11.21
(3.40 to 36.89)
⊕◯◯◯
VERY LOW
11.21 (3.4–36.89)
11 fewer per 1,000
(from 37 fewer to 3 fewer)
⊕◯◯◯a,b,c
VERY LOW
DHP vs CQ NA NA 16.54
(5.02–54.56)
⊕⊕◯◯
LOW
16.54
(5.02 to 24.56)
17 fewer per 1,000
(from 25 fewer to 5 fewer
⊕⊕◯◯a,b
LOW
DHP vs ASSP NA NA 0.01 (0.00–0.04) ⊕⊕◯◯
LOW
0.01
(0.00 to 0.04)
0 fewer per 1,000
(from—to 0 fewer)
⊕⊕◯◯a,b
LOW
ASCQ vs AL NA NA 0.22 (0.06–0.79) ⊕⊕◯◯
LOW
0.22 (0.06–0.79)
0 fewer per 1,000
(from 1 fewer to 0 fewer)
⊕⊕◯◯a
LOW
ASAQ vs AL NA NA 5.55 (0.26–119.75) ⊕◯◯◯
VERY LOW
5.55 (0.26–119.75)
6 fewer per 1,000
(from 120 fewer to 0 fewer)
⊕◯◯◯a,b,d
VERY LOW
CI: Confidence interval; OR: Odds ratio; Explanations: a. studies at unclear and high risk of bias; b. wide predictive interval; c. very wide CI; d. wide 95%CI and it
crossed a null value; e: a singular study at high risk of bias; f. a singular study
https://doi.org/10.1371/journal.pone.0225882.t002
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intervention is needed. Some RCTs included were done with small sample size and they also
had low methodological quality. Hence, there was a concern to the confidence in the effect esti-
mates. Due to lack of blinding in some RCTs included, the risk of performance bias is a con-
cern. Myanmar has substantially more malaria than any other country in the Southeast Asia
[45]. The current analysis included only one RCT from Myanmar, indicating a limited geo-
graphical representativeness and an interpretation of the findings was limited with regard to
generalizability.
Implications
There is evidence that DHP has better treatment outcome than monotherapy such as SP and
CQ, which are almost completely ineffective in Southeast Asia due to drug resistance.
Evidence from RCTs may not apply to real-world practice, where people in need of antima-
larial treatment are often limited to compliance due to unsupervised treatment and lack of
monitoring. Further studies should be directed to detect the effectiveness in real-world prac-
tice and should also focus on monitoring and treatment regimens. Moreover, in the light of
benefit versus harm concept, a NMA of the relative safety of different antimalarial treatment is
needed.
Fig 4. Network meta-analysis of antimalarial treatments.
https://doi.org/10.1371/journal.pone.0225882.g004
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Conclusions
The findings suggest the superiority of DHP to AL and other comparator ACTs are with the
overall low/very low quality of evidence judgements. Moreover, one drug regimen is better
than another is only, if current drug-resistance patterns are at play. For example, the AL might
be better than DHP in areas where both artemisinin and piperaquine resistance patterns are
prevalent [7,9]. For substantiation, well-designed larger trials from endemic countries are
needed. In the light of benefit versus harm concept, future analysis with safety information is
recommended.
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